GnRH agonist leuprolide depot 1-month
Selected indexed studies
- Clinical development of the GnRH agonist leuprolide acetate depot. (F S Rep, 2023) [PMID:37223757]
- Clinical pharmacokinetics of depot leuprorelin. (Clin Pharmacokinet, 2002) [PMID:12083977]
- Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer. (Int J Clin Oncol, 2013) [PMID:22552359]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical development of the GnRH agonist leuprolide acetate depot. (2023) pubmed
- Clinical pharmacokinetics of depot leuprorelin. (2002) pubmed
- Comparison of efficacy and safety of 1- and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer. (2013) pubmed
- Leuprorelin acetate granulomas: case reports and review of the literature. (2005) pubmed
- Degarelix: a new approach for the treatment of prostate cancer. (2009) pubmed
- [A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-Nazve patients with prostatic cancer who received a single subcutaneous or intramuscular injection]. (2014) pubmed
- Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. (2010) pubmed
- Microencapsulation of luteinizing hormone-releasing hormone agonist in poly (lactic-co-glycolic acid) microspheres by spray-drying. (2020) pubmed
- Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. (2017) pubmed
- Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. (2002) pubmed